In one ~~aspect~~example, the present disclosure refers to a combination of 4,4,4-trifluoro-N-[(1S)-2-[[(7S)-5-(2-hydroxyethyl)-6-oxo-7H-pyrido[2,3-d][3]benzazepin-7-yl]amino]-1-methyl-2-oxo-ethyl]butanamide, or a pharmaceutically acceptable salt or hydrate thereof; and a PD-1 or PD-L1 inhibitor selected from the group consisting of pembrolizumab, nivolumab, atezolizumab, durvalumab, and avelumab for use in combination therapy for the treatment of colorectal cancer.

Disclosed is a compound 4,4,4-trifluoro-N-[(1S)-2-[[(7S)-5-(2-hydroxyethyl)-6-oxo-7H-pyrido[2,3-d][3]benzazepin-7-yl]amino]-1-methyl-2-oxo-ethyl]butanamide, or a pharmaceutically acceptable salt or hydrate thereof; and a PD-1 or PD-L1 inhibitor selected from pembrolizumab, nivolumab, atezolizumab,

WE CLAIM:

~~1. A combination of 4,4,4-trifluoro-N-[(1S)-2-[[(7S)-5-(2-hydroxyethyl)-6-oxo-7H-pyrido[2,3-d][3]benzazepin-7-yl]amino]-1-methyl-2-oxo-ethyl]butanamide, or a pharmaceutically acceptable salt or hydrate thereof; and a PD-1 or PD-L1 inhibitor selected from the group consisting of pembrolizumab, nivolumab, atezolizumab, durvalumab, and avelumab for use in combination therapy for the treatment of colorectal cancer.~~

~~2. The combination for use according to claim 1, wherein the 4,4,4-trifluoro-N-[(1S)-2-[[(7S)-5-(2-hydroxyethyl)-6-oxo-7H-pyrido[2,3-d][3]benzazepin-7-yl]amino]-1-methyl-2-oxo-ethyl]butanamide, or the pharmaceutically acceptable salt or hydrate thereof, and the PD-1 or PD-L1 inhibitor are to be administered simultaneously, separately, or sequentially.~~

~~3. The combination for use according to claim 1 or claim 2, wherein the 4,4,4-trifluoro-N-[(1S)-2-[[(7S)-5-(2-hydroxyethyl)-6-oxo-7H-pyrido[2,3-d][3]benzazepin-7-yl]amino]-1-methyl-2-oxo-ethyl]butanamide, or the pharmaceutically acceptable salt or hydrate thereof is to be administered in an amount between 2.5 mg and 75 mg once per day every other day over a five day period followed by two days without dosing (T.I.W.).~~

~~4. The combination for use according to any of claims 1-3, wherein the 4,4,4-trifluoro-N-[(1S)-2-[[(7S)-5-(2-hydroxyethyl)-6-oxo-7H-pyrido[2,3-d][3]benzazepin-7-yl]amino]-1-methyl-2-oxo-ethyl]butanamide, or the pharmaceutically acceptable salt or hydrate thereof is to be administered in an amount between 10 mg and 50 mg T.I.W.~~

~~5. The combination for use according to any of claims 1-4, wherein the 4,4,4-trifluoro-N-[(1S)-2-[[(7S)-5-(2-hydroxyethyl)-6-oxo-7H-pyrido[2,3-d][3]benzazepin-7-yl]amino]-1-methyl-2-oxo-ethyl]butanamide, or the pharmaceutically acceptable salt or hydrate thereof is to be administered orally.~~

~~6. The combination for use according to any of claims 1-5, wherein the PD-1 or PD-L1 inhibitor is to be administered in an amount between 1 mg/kg and 3 mg/kg once every 14 to 21 days.~~

~~7. The combination for use according to any of claims 1-6, wherein the PD-1 or PD-L1 inhibitor is to be administered parenterally.~~

~~8. The combination for use according to claim 7, wherein the parenteral administration is intravenous infusion.~~

19. Use of 4,4,4-trifluoro-N-[(1S)-2-[[(7S)-5-(2-hydroxyethyl)-6-oxo-7H-pyrido[2,3-d][3]benzazepin-7-yl]amino]-1-methyl-2-oxo-ethyl]butanamide, or a pharmaceutically acceptable salt or hydrate thereof in the manufacture of a first medicament; and use of a PD-1 or PD-L1 inhibitor selected from the group consisting of pembrolizumab, nivolumab, atezolizumab, durvalumab, and avelumab in the independent manufacture of a second medicament; for the treatment of colorectal cancer, wherein the first medicament and the second medicament are to be administered in combination.

210. The use of claim 19, wherein the 4,4,4-trifluoro-N-[(1S)-2-[[(7S)-5-(2-hydroxyethyl)-6-oxo-7H-pyrido[2,3-d][3]benzazepin-7-yl]amino]-1-methyl-2-oxo-ethyl]butanamide, or the pharmaceutically acceptable salt or hydrate thereof, and the PD-1

or PD-L1 inhibitor are to be administered simultaneously, separately, or sequentially.

311. The use of claim 19 or claim 210, wherein the first medicament comprises between 2.5 mg and 75 mg of 4,4,4-trifluoro-N-[(1S)-2-[[(7S)-5-(2-hydroxyethyl)-6-oxo-7H-pyrido[2,3-d][3]benzazepin-7-yl]amino]-1-methyl-2-oxo-ethyl]butanamide, or a pharmaceutically acceptable salt or hydrate thereof.

412. The use of claim 311, wherein the first medicament comprises between 10 mg and 50 mg of 4,4,4-trifluoro-N-[(1S)-2-[[(7S)-5-(2-hydroxyethyl)-6-oxo-7H-pyrido[2,3-d][3]benzazepin-7-yl]amino]-1-methyl-2-oxo-ethyl]butanamide, or a pharmaceutically acceptable salt or hydrate thereof.

513. The use of any of claims 19-311, wherein the first medicament is to be administered in an amount between 2.5 mg and 75 mg once per day every other day over a five day period followed by two days without dosing (T.I.W.).

614. The use of any of claims 19-412, wherein the first medicament is to be administered in an amount between 10 mg and 50 mg T.I.W.

715. The use of any of claims 19-614, wherein the first medicament is to be administered orally.

816. The use of any of claims 19-715, wherein the second medicament is to be administered in an amount between 1 mg/kg and 3 mg/kg once every 14 to 21 days.

917. The use of any of claims 19-816, wherein the second medicament is to be administered parenterally.

1018. The use of claim 917, wherein the parenteral administration is intravenous infusion.